Securities Registration: Employee Benefit Plan (s-8)
March 15 2018 - 6:07AM
Edgar (US Regulatory)
As filed with the Securities and Exchange Commission on March 14, 2018
Registration Statement No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
S-8
REGISTRATION STATEMENT
UNDER
THE
SECURITIES ACT OF 1933
PROTEOSTASIS THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
Delaware
|
|
20-8436652
|
(State or other jurisdiction of
incorporation or organization)
|
|
(I.R.S. Employer
Identification No.)
|
200 Technology Square, 4th Floor,
Cambridge, Massachusetts 02139
(Address of principal executive offices) (Zip Code)
Proteostasis Therapeutics, Inc. 2016 Stock Option and Incentive Plan
Proteostasis Therapeutics, Inc. 2016 Employee Stock Purchase Plan
(Full title of the plan)
Meenu Chhabra
President
and Chief Executive Officer
Proteostasis Therapeutics, Inc.
200 Technology Square, 4th Floor
Cambridge, Massachusetts
(Name and address of agent for service)
(617) 225-0096
(Telephone number, including area code, of agent for service)
With copies to:
|
|
|
Jeff Held
General Counsel
Proteostasis Therapeutics, Inc.
200 Technology Square, 4th Floor
Cambridge, Massachusetts 02139
|
|
Mitchell S. Bloom, Esq.
John M. Mutkoski, Esq.
Goodwin Procter LLP
100
Northern Avenue
Boston, Massachusetts 02109
(617) 570-1000
|
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an
emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act.
|
|
|
|
|
|
|
Large accelerated filer
|
|
☐
|
|
Accelerated filer
|
|
☒
|
|
|
|
|
Non-accelerated filer
|
|
☐ (Do not check if a smaller reporting company)
|
|
Smaller reporting company
|
|
☐
|
|
|
|
|
|
|
|
|
Emerging growth company
|
|
☒
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☒
CALCULATION
OF REGISTRATION FEE
|
|
|
|
|
|
|
|
|
|
Title of securities to be registered
|
|
Amount to be
registered
(1)
|
|
Proposed
maximum
offering price
per share
(2)
|
|
Proposed
maximum
aggregate
offering price
(2)
|
|
Amount of
registration
fee
(2)
|
2016 Stock Option and Incentive Plan
Common Stock, $0.001 par value per share
|
|
1,032,482 shares
(3)
|
|
$4.06
|
|
$4,191,876.92
|
|
$521.89
|
2016 Employee Stock Purchase Plan
Common Stock, $0.001 par value per share
|
|
138,757 shares
(4)
|
|
$4.06
|
|
$563,353.42
|
|
$70.14
|
Total
|
|
1,171,239 shares
|
|
|
|
|
|
$592.03
|
|
|
(1)
|
Pursuant to Rule 416 under the Securities Act of 1933, as amended (the Securities Act), this Registration Statement shall also cover any additional shares of common stock which become issuable under the
above-named plans by reason of any stock dividend, stock split, recapitalization or any other similar transaction effected without the receipt of consideration which results in an increase in the number of our outstanding shares of common stock.
Pursuant to Rule 416(c) under the Securities Act, this Registration Statement shall also cover an indeterminate amount of interests to be offered or sold pursuant to the employee benefit plans described herein.
|
(2)
|
Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457 of the Securities Act, and based on $4.06, the average of the high and low sale prices of the registrants common stock as
reported on the Nasdaq Global Market on March 12, 2018.
|
(3)
|
Represents an automatic increase to the number of shares available for issuance under the registrants 2016 Stock Option and Incentive Plan (the Plan), effective as of January 1, 2018. Shares available
for issuance under the Plan were previously registered on registration statements on Form S-8 filed with the Securities and Exchange Commission on March 31, 2016 (Registration No. 333-210521).
|
(4)
|
Represents an automatic increase to the number of shares available for issuance under the registrants 2016 Employee Stock Purchase Plan (the ESPP), effective as of January 1, 2018. Shares available for
issuance under the ESPP were previously registered on registration statements on Form S-8 filed with the Securities and Exchange Commission on March 31, 2016 (Registration No. 333-210521).
|
EXPLANATORY NOTE
This Registration Statement registers additional securities of the same class as other securities for which a registration statement filed on Form S-8
(Registration No. 333-210521) of the Registrant is effective. The information contained in the Registrants registration statement on Form S-8 (Registration No. 333-210521) is hereby incorporated by reference pursuant to General
Instruction E.
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
See the Exhibit Index on the page immediately preceding the exhibits for a list of exhibits
filed as part of this registration statement, which Exhibit Index is incorporated herein by reference.
INDEX TO EXHIBITS
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the
requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Cambridge, State of Massachusetts, on March 14, 2018.
|
|
|
PROTEOSTASIS THERAPEUTICS, INC.
|
|
|
By:
|
|
/s/ Meenu Chhabra
|
|
|
Meenu Chhabra
President and Chief Executive
Officer
|
POWER OF ATTORNEY
We, the undersigned officers and directors of Proteostasis Therapeutics, Inc., hereby severally constitute and appoint Meenu Chhabra and Jeff Held, and each of
them, with full power of substitution and resubstitution and full power to act without the other, as his or her true and lawful attorney in fact and agent to act in his or her name, place and stead, and in any and all capacities, to sign any and all
amendments (including post-effective amendments) to this registration statement, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said
attorney-in-fact and agent, full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises, as full to all intents and purposes as she or he might or could do in person, hereby
ratifying and confirming all that said attorney-in-fact and agent or her or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities
and on the date indicated.
|
|
|
|
|
/s/ Meenu Chhabra
|
|
President, Chief Executive Officer and Director
|
|
March 14, 2018
|
Meenu Chhabra
|
|
(Principal Executive Officer)
|
|
|
|
|
|
/s/ Helen Boudreau
|
|
Chief Financial Officer
|
|
March 14, 2018
|
Helen Boudreau
|
|
(Principal Financial and Accounting Officer)
|
|
|
|
|
|
/s/ M. James Barrett
|
|
Chairman of the Board of Directors
|
|
March 14, 2018
|
M. James Barrett, Ph.D.
|
|
|
|
|
|
|
|
/s/ Franklin M. Berger
|
|
Director
|
|
March 14, 2018
|
Franklin M. Berger, CFA
|
|
|
|
|
|
|
|
/s/ Jeffery W. Kelly
|
|
Director
|
|
March 14, 2018
|
Jeffery W. Kelly, Ph.D.
|
|
|
|
|
|
|
|
/s/ Eric B. Rabinowitz
|
|
Director
|
|
March 14, 2018
|
Eric B. Rabinowitz
|
|
|
|
|
Proteostasis Therapeutics (NASDAQ:PTI)
Historical Stock Chart
From Apr 2024 to May 2024
Proteostasis Therapeutics (NASDAQ:PTI)
Historical Stock Chart
From May 2023 to May 2024